Cases of new variant of corona virus JN.1 are increasing in the country.
Advisories have been issued by different state governments regarding this. Meanwhile, the question is arising in the minds of people whether they will now have to get vaccinated against this new variant.
Indian vaccine manufacturing company Serum Serum Institute has given a big update regarding this. Serum says that preparations are underway to apply for a license for the vaccine made against the new variant.
According to media reports, Serum spokesperson said that the new vaccine is expected to be approved soon.
He said, ‘We are currently offering the XBB1 variant vaccine which is similar to the JN1 variant in the US and Europe. Our aim is to obtain a license for this vaccine in India in the coming months.
We are preparing to submit the necessary documents to the regulators with the aim of making it available to the people.
Serum Institute had made Covishield vaccine
It is known that Serum Institute has earlier manufactured Covishield vaccine against Corona in India. On January 1, 2021, the Drug Controller General of India (DCGI) approved the emergency use of the Oxford-AstraZeneca vaccine (Covishield). This vaccine has been approved in 49 countries.
The company also manufactures Covovax under license from US-based vaccine maker Novavax Inc.
Serum Institute was set up as a partnership firm in 1966 by the Poonawalla Group headed by Dr. Cyrus S. Poonawalla to manufacture vaccines. It was recognized as a public limited company in May 1984 and then as a private limited company in October 2015.
594 new cases of corona infection on Thursday
It is noteworthy that 594 new cases of corona virus infection were registered in India on Thursday, due to which the number of patients under treatment increased to 2,669 which was 2,331 a day before.
According to Union Health Ministry data, the total number of Covid-19 cases in the country reached 4.50 crore (4,50,06,572). After the death of 6 patients, the death toll increased to 5,33,327 in which three patients lost their lives in Kerala, two in Karnataka and one in Punjab.
The number of people recovering from this disease has increased to 4,44,70,576 and the national recovery rate is 98.81 percent.
The rate of loss of life due to infection is 1.19 percent. So far, 220.67 crore doses have been given in the country under the anti-Covid-19 vaccination campaign.